Based on the latest published data, global prevalence of type 1 diabetes (T1D) was 8.4 million individuals in 2021, with 18 % of them being younger than 20 years, 64 % aged 20–59 years and 19 % aged 60 years or older [1]. Global prevalence of T1D is expected to increase by 13.5 to 17.4 million people in 2040, whereas T1D, especially if diagnosed during early childhood, is associated with a significant decrease in life expectancy [1]. Insulin treatment remains the mainstay of T1D treatment, however, despite the significant progress made in insulin delivery systems and overall diabetes technology, glycaemic control among individuals with T1D remains suboptimal [2].
